Billiontoone (NASDAQ:BLLN) Trading 3.2% Higher – Should You Buy?

Billiontoone, Inc. (NASDAQ:BLLN)’s stock price rose 3.2% during mid-day trading on Friday . The stock traded as high as $89.99 and last traded at $89.09. Approximately 45,845 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 207,081 shares. The stock had previously closed at $86.34.

Analyst Ratings Changes

Several brokerages have issued reports on BLLN. Stifel Nicolaus started coverage on Billiontoone in a research note on Monday, December 1st. They set a “buy” rating and a $145.00 price target for the company. William Blair began coverage on Billiontoone in a report on Monday, December 1st. They set an “outperform” rating on the stock. JPMorgan Chase & Co. cut their target price on Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Wednesday, December 10th. BTIG Research reiterated a “buy” rating and set a $160.00 price target on shares of Billiontoone in a research report on Wednesday, December 10th. Finally, Wall Street Zen upgraded shares of Billiontoone to a “hold” rating in a report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $137.83.

Billiontoone Stock Performance

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Tuesday, December 9th. The company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.06). The firm had revenue of $83.52 million during the quarter, compared to analysts’ expectations of $82.86 million.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.